1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/42648
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGoh S.en
dc.contributor.authorSuriadi C.en
dc.contributor.authorGani L.U.en
dc.contributor.authorMilat F.en
dc.contributor.authorAllan C.A.en
dc.contributor.authorStrickland A.H.en
dc.contributor.authorTeede H.J.en
dc.contributor.authorFuller P.J.en
dc.contributor.authorGillespie M.T.en
dc.date.accessioned2021-05-14T14:38:09Zen
dc.date.available2021-05-14T14:38:09Zen
dc.date.copyright2013en
dc.date.created20130607en
dc.date.issued2013-06-07en
dc.identifier.citationBone. 55 (2) (pp 305-308), 2013. Date of Publication: August 2013.en
dc.identifier.issn8756-3282en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/42648en
dc.description.abstractProstate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26. days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function. © 2013 .en
dc.languageenen
dc.languageEnglishen
dc.publisherElsevier Inc. (360 Park Avenue South, New York NY 10010, United States)en
dc.titleProlonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.en
dc.typeArticleen
dc.type.studyortrialCase series or case report-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.bone.2013.04.012en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid23685544 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23685544]en
dc.identifier.source368983287en
dc.identifier.institution(Milat, Goh, Gani, Fuller, Teede, Allan) Department of Endocrinology, Monash Health, Monash Medical Centre, Clayton, Australia (Milat, Gillespie, Fuller) Bone Joint and Cancer Unit, Prince Henry's Institute, Block E, Level 4, Monash Medical Centre, Clayton, Australia (Milat, Fuller, Allan) Department of Medicine, Southern Clinical School, Monash University, Clayton, Australia (Suriadi, Strickland) Monash Cancer Centre, Centre Rd, Bentleigh, Australia (Gillespie, Fuller) Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia (Teede) School of Public Health and Preventive Medicine, Monash University, Clayton, Australiaen
dc.description.addressF. Milat, Bone Joint and Cancer Unit, Prince Henry's Institute, Block E, Level 4, Monash Medical Centre, Clayton, VIC, Australia. E-mail: fran.milat@princehenrys.orgen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2013 Elsevier B.V., All rights reserved.en
dc.subect.keywordsBone Denosumab Hypocalcemia Prostate canceren
dc.identifier.authoremailMilat F.; fran.milat@princehenrys.orgen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptDiabetes and Vascular Medicine-
Appears in Collections:Articles
Show simple item record

Page view(s)

8
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.